Instituto Biológico Argentino S.A.I.C.

What Instituto Biológico Argentino S.A.I.C. does

Instituto Biológico Argentino S.A.I.C. (BIOL) is an Argentine privately-held pharmaceutical company founded in 1908, specializing in the development, manufacturing, and commercialization of biological and specialty pharmaceutical products. Its core portfolio is anchored in injectables, semi-solid formulations, vaccines, and antisera, with additional therapeutic lines spanning critical care medicine, women's health, antibiotics, and dermatologicals. BIOL operates two production sites—a Buenos Aires headquarters and a Florencio Varela manufacturing facility—and employs between 51 and 100 people.

The company operates a three-channel revenue model: (1) direct sales of its own branded pharmaceutical products, (2) third-party contract manufacturing services for external clients using its Florencio Varela capacity, and (3) international laboratory representation, where BIOL acts as the local Argentine distributor and marketing partner for foreign pharmaceutical laboratories seeking market entry. Its commercial reach targets hospitals, healthcare institutions, and healthcare professionals, with exports extending its footprint beyond Argentina into international markets.

BIOL's strategic posture reflects a legacy Argentine pharmaceutical operator combining branded specialty pharma, B2B manufacturing services, and import/distribution representation. No public financial statements, funding rounds, ownership structure beyond private status, named major customers, or specific leadership disclosures are available. The company's positioning in high-barrier biological categories (vaccines, antisera) and its century-plus regulatory standing provide defensive characteristics, while the absence of disclosed growth metrics, AI capability, or recent capital activity limits visibility into its current expansion trajectory.

Name

Instituto Biológico Argentino S.A.I.C.

Legal name

Instituto Biológico Argentino S.A.I.C.

Website

https://biol.com.ar

Company type

Private

Founded year

1908

Operating status

Operating

Headcount range

101–250 employees

Short description

Instituto Biológico Argentino S.A.I.C. (BIOL) is a 1908-founded Argentine pharmaceutical company that develops, manufactures, and distributes injectables, vaccines, antisera, and specialty therapeutics for hospitals and healthcare institutions, while also offering contract manufacturing and representing international laboratories in Argentina.

Ownership category

akta.pro rank

Headquarters

HQ city

Casa Bamba

HQ country

Argentina

HQ region

Latin America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Supply Chain, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Product Sales: Manufacturing and commercialization of pharmaceutical products including injectables, semi-solid, and biological products for healthcare institutions, hospitals, and healthcare professionals.
2. Third-Party Manufacturing Services: Contract manufacturing of injectables, semi-solid and biological products for other pharmaceutical companies; conducting bioassays for pharmaceutical companies.
3. International Representation: Representing important international laboratories in Argentina, distributing their pharmaceutical products in the domestic market.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels2 records

Core offering

Instituto Biológico Argentino S.A.I.C. (BIOL) manufactures and commercializes injectable, semi-solid, and biological pharmaceutical products, including vaccines (BCG, tetanus, diphtheria-tetanus, influenza), antisera (polyvalent and Central American antivenoms), critical care injectables (oxytocin, methylergometrine, adrenaline, noradrenaline, dopamine, dexmedetomidine), antibiotics, anesthetics, hormones, women's health and dermatological products. The company also provides contract manufacturing services for third parties (injectables, semi-solids, biologicals, and bioassays) and represents international laboratories in the Argentine market.

Product overview

Instituto Biológico Argentino S.A.I.C. (BIOL) is a privately-funded Argentine pharmaceutical company founded in 1908 that manufactures and markets pharmaceutical products. The company specializes in three main product categories: injectables (including ampoules, vials, and pre-filled syringes), semi-solid products (creams, ointments, and gels), and biological products (vaccines, antisera, and tuberculin). The product portfolio is organized into therapeutic lines including: Biologicals (vaccines such as BCG SSI, Tetanus TT, Diphtheria-Tetanus dTa, Influenza NILGRIP®, and polyvalent anti-infectious vaccines; antisera including polyvalent antivenom and Central American antivenom; tuberculin PPD RT23); Critical Care/Emergency products (oxytocin HIPOFISINA®, ergonovine METRERGINA®, vasopressin NOVOPRESSINA-V®, adrenaline ADRENALINA BIOL, noradrenaline NORADRENALINA BIOL, dopamine DOPAMINA BIOL, dexmedetomidine VALERTROPINA®, rocuronium, furosemide); Women's Health products (inositol INOFOLIC, bacterial lysates LAETIS®, oxytocin, ergonovine); Hospital products (adhesives/antiseptics FRONT®); Skin Care products (SODERMIX® for scars, QUASIX® for rosacea); and Antibiotics/Antimicrobials (ceftriaxone, gentamicin, clindamycin, metronidazole). The company operates pharmaceutical manufacturing facilities in Florencio Varela, Buenos Aires, and exports products internationally while also providing contract manufacturing services (bioassays) for other pharmaceutical companies.

Differentiator

Problem solved

Functional benefit

Brands

• BIOL: Primary brand/trademark under which the company manufactures and markets its pharmaceutical products including injectables, semi-solids and biological products.
• Biol Ofidismo

Products and services

• SUERO ANTIOFIDICO POLIVALENTE BIOL (Polyvalent Antivenom Serum) Polyvalent antivenom serum used to treat snake bites; intended for hospitals, emergency services, and poison control centers.
• Antivenom Serum (Central American lineage) Antivenom serum formulated for envenomation from Central American snake species; for hospitals and emergency services.
• VACUNA BCG SSI (BCG Vaccine) BCG vaccine for tuberculosis immunization, marketed by BIOL for use in vaccination programs and clinical settings.
• Tetanus Vaccine (BIOL) Tetanus vaccine for active immunization against tetanus; for hospitals, public health programs, and immunization campaigns.
• Diphtheria-Tetanus Adult Vaccine (BIOL) Combined diphtheria-tetanus vaccine for adult immunization; used by hospitals and public health immunization programs.
• NILGRIP (Influenza Vaccine) Influenza vaccine for seasonal immunization; for hospitals, occupational health programs, and vaccination campaigns.
• Tuberculin PPD RT23 Purified protein derivative (PPD) tuberculin for tuberculosis diagnosis via skin test; used by hospitals, clinics, and occupational health services.
• HIPOFISINA (Oxytocin) Oxytocin injectable for obstetric use (labor induction/augmentation and postpartum hemorrhage control); for hospitals and maternity wards.
• METRERGINA (Methylergometrine) Methylergometrine injectable for prevention and treatment of postpartum hemorrhage; for obstetric hospitals and maternity units.
• ADRENALINA BIOL (Adrenaline/Epinephrine) Adrenaline (epinephrine) injectable for emergency cardiovascular and anaphylaxis management; for hospitals, emergency rooms, and intensive care units.
• NORADRENALINA BIOL (Noradrenaline/Norepinephrine) Noradrenaline (norepinephrine) injectable for acute hypotension and shock management; for ICU and emergency hospital use.
• DOPAMINA BIOL (Dopamine) Dopamine injectable for shock, low cardiac output, and hemodynamic support; for ICU and critical care settings.
• VALERTROPINA (Dexmedetomidine) Dexmedetomidine injectable for sedation in ICU and procedural settings; for hospitals and critical care units.
• INOFOLIC (Myo-Inositol + Folic Acid) Combination of myo-inositol and folic acid used in women's reproductive health and metabolic support; for pharmacies, fertility specialists, and obstetric practices.
• LAETIS Women's health product marketed by BIOL.
• OCITOCINA (Oxytocin) Oxytocin product in BIOL's women's health portfolio for obstetric use.
• SODERMIX Dermatological semi-solid preparation distributed by BIOL.
• QUASIX Dermatological semi-solid preparation distributed by BIOL.
• FRONT Hospital pharmaceutical product in BIOL's general hospital portfolio.
• CEFTRIAXONA BIOL (Ceftriaxone) Ceftriaxone injectable antibiotic for serious bacterial infections; for hospital use.
• GENTAMICINA BIOL (Gentamicin) Gentamicin injectable antibiotic for bacterial infections; for hospital use.
• Contract Manufacturing Services Contract manufacturing of injectables, semi-solid formulations, and biological products for third-party pharmaceutical companies; offered at BIOL's Florencio Varela plant.
• Bioassay Services Bioassay laboratory services supporting biological product testing for third-party clients.
• International Laboratory Representation in Argentina Representation, registration, marketing and distribution of international pharmaceutical laboratory products in the Argentine market.

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Two partnerships are on record, tiered core.

• Various International LaboratoriescoreChannel Partner/ Reseller/ DistributorBIOL serves as representative for important international pharmaceutical laboratories in Argentina, distributing their products within the domestic market. This partnership enables BIOL to offer a comprehensive portfolio of pharmaceutical products to healthcare institutions.
• Pharmaceutical Companies (Third-Party Services)coreImplementation/ SI/ Consulting PartnerBIOL manufactures injectables, semi-solid and biological products for other pharmaceutical companies and conducts bioassays. These companies trust BIOL for their manufacturing capabilities and quality assurance.

Scale indicators2 records

Recent moves5 records

Expansion highlights4 records

Direct peers

• Laboratorios Richmond: Argentine pharmaceutical manufacturer with a strong vaccines and biologicals franchise (including COVID-19 vaccine partnerships). Directly comparable as a domestically based Argentine manufacturer of injectables, vaccines, and specialty pharmaceuticals serving institutional channels.
• Sinergium Biotech: Argentine biopharmaceutical company focused on vaccines, biologicals, and sterile injectable contract manufacturing. Closely comparable to BIOL's biologicals and contract-manufacturing capabilities and its role in the Argentine public vaccine supply chain.
• mAbxience: Argentine-based biosimilars and biological contract manufacturer with global Grupo Insud ownership. Comparable as a Latin American biologicals manufacturer leveraging contract development and manufacturing services to multinational pharma clients.

Broad incumbents

• Laboratorios Bagó: One of the largest Argentine pharmaceutical groups with broad prescription, OTC, and hospital portfolios including injectables. Comparable as a much larger Argentine incumbent operating across overlapping therapeutic categories and institutional channels.
• Laboratorios Roemmers: Leading Argentine pharmaceutical company with a wide branded specialty and hospital portfolio. Comparable as a broad Argentine pharma incumbent competing with BIOL for institutional hospital tender business across multiple therapeutic lines.
• Gador: Established Argentine pharmaceutical manufacturer with branded generics, oncology, and hospital injectable lines. Comparable as an Argentine incumbent with overlapping injectables and institutional-channel exposure.
• Elea Phoenix: Major Argentine pharmaceutical company covering women's health, CNS, and hospital therapeutics. Comparable as a domestic peer with overlapping OB/GYN and specialty pharmaceutical categories served through similar institutional channels.
• Sanofi Pasteur: Global vaccines division of Sanofi, including one of the few other producers of antivenoms worldwide. Comparable as a multinational biologicals/vaccines manufacturer whose portfolio and capabilities overlap directly with BIOL's vaccines and antisera lines.
• CSL Seqirus / CSL Limited: Global biotherapeutics and influenza vaccine producer with antivenom heritage. Comparable as a multinational player in biologicals with overlapping capabilities in antisera/antivenoms and vaccine manufacturing at a vastly larger scale.

Emerging players

• Inmunova: Argentine biotech developing antivenoms and therapeutic antibodies for snakebite and other neglected diseases. Comparable as an emerging Latin American player addressing the same niche antivenom market where BIOL's Central American antivenom is positioned.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• YouTubeyoutube.com/channel/UCzRUA9UIa_xtoN2Qdyr1d8w/featured
• Facebookfacebook.com/LaboratorioBiol
• LinkedInlinkedin.com/company/instituto-biologico-argentino-s.a.i.c.

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Instituto Biológico Argentino S.A.I.C.